Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-9768 in Primary IgA Nephropathy, C3 Glomerulopathy, and IC-MPGN
NCT06786338Phase 2Active, not recruiting
- Sponsor
- SanegeneBio
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of SGB-9768 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), sponsored by SanegeneBio. Started Jun 2025; status: active, not recruiting.
02
Drugs
SGB-9768
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT06786338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786338.